Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Synthetic Anti-infective Drugs >  Antiviral drugs >  Zidovudine


Basic information Safety Related Supplier
Zidovudine Basic information
Zidovudine Chemical Properties
  • Melting point:113-115 °C(lit.)
  • alpha D25 +99° (c = 0.5 in water)
  • Boiling point:410.43°C (rough estimate)
  • Density 1.3382 (rough estimate)
  • refractive index 47 ° (C=1, H2O)
  • Flash point:9℃
  • storage temp. −20°C
  • solubility H2O: 50 mg/mL
  • pkapKa 9.53(H2O t = 25.0±0.1 I = 0.00) (Uncertain)
  • form Powder
  • color White to Off-white
  • Water Solubility 1-5 g/100 mL at 17 ºC
  • Sensitive Light Sensitive & Hygroscopic
  • Merck 14,10123
  • BRN 3595791
  • CAS DataBase Reference30516-87-1(CAS DataBase Reference)
  • EPA Substance Registry SystemThymidine, 3'-azido-3'-deoxy- (30516-87-1)
Safety Information
  • Hazard Codes Xn
  • Risk Statements 40-36/37/38-20/21/22
  • Safety Statements 36/37/39-45-36-26
  • RIDADR UN1230 - class 3 - PG 2 - Methanol, solution
  • WGK Germany 3
  • RTECS XP2072000
  • 10
  • Hazard Note Harmful
  • HS Code 29349990
  • Hazardous Substances Data30516-87-1(Hazardous Substances Data)
  • ToxicityLD50 in male, female mice, male, female rats (mg/kg): 3568, 3062, 3084, 3683 orally; >750 i.v. (all species) (Ayers)
Zidovudine Usage And Synthesis
  • DescriptionZidovudine, also known as azidothymidine (AZT), is an antiviral agent acting via reverse transcnptase inhibition. It was first launched in the U.K. and subsequently introduced in over a dozen countries for the management of severe manifestations of HIV infection. In patients with AIDS and ARC, zidovudine reduces the risk of opportunistic infections and prolongs survival time. In symptom-free patients it shows promise in halting further immunological deterioration.
  • Chemical PropertiesOff White Crystalline Powder
  • OriginatorDetroit Inst. Cancer Res. (USA)
  • UsesA potent and selective inhibitor of HIV-1 replication
  • Usesantibacterial
  • DefinitionChEBI: A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.
  • IndicationsZidovudine was the first agent to be used to prevent the transmission of HIV from a pregnant woman to her child. It was given to the mother at 14 to 34 weeks’ gestation and to the child for the first 6 weeks of life. Current combination therapies employ zidovudine with another NRTI and a protease inhibitor.
  • brand nameRetrovir (GlaxoSmithKline).
  • Antimicrobial activityZidovudine is active against HIV-1, HIV-2 and HTLV-1.
  • Acquired resistanceAs with stavudine, mutations at position 41, 67 and 70, and positions 210, 215 and 219 (the ‘thymidine analog mutations’) of the reverse transcriptase genes are associated with diminished antiretroviral efficacy.
  • General DescriptionSlightly off-white odorless powdery solid.
  • General DescriptionZidovudine, 3'-azido-3'-deoxythymidine or AZT, is ananalog of thymidine that possesses antiviral activityagainst HIV-1, HIV-2, HTLV-1, and several other retroviruses.This nucleoside was synthesized in 1978 by Linand Prusoff as an intermediate in the preparation ofamino acid analogs of thymidine. A screening program directedtoward the identification of agents potentially effectivefor the treatment of patients with AIDS led to the discoveryof its unique antiviral properties 7 years later.
    Zidovudine is recommended for the management of adultpatients with symptomatic HIV infection (AIDS or ARC)who have a history of confirmed Pneumocystis carinii pneumoniaor an absolute CD4+(T4 or TH cell) lymphocytecount below 200/mm3 before therapy. The hematologicaltoxicity of the drug precludes its use in asymptomatic patients.Anemia and granulocytopenia are the most commontoxic effects associated with AZT.
  • Air & Water ReactionsDust may form an explosive mixture in air. Water soluble. Hydrolysis occurs in strongly basic solutions .
  • Reactivity ProfileZidovudine is a azido compound. Azo, diazo, azido compounds can detonate. This applies in particular to organic azides that have been sensitized by the addition of metal salts or strong acids. Toxic gases are formed by mixing materials of this class with acids, aldehydes, amides, carbamates, cyanides, inorganic fluorides, halogenated organics, isocyanates, ketones, metals, nitrides, peroxides, phenols, epoxides, acyl halides, and strong oxidizing or reducing agents. Flammable gases are formed by mixing materials in this group with alkali metals. Explosive combination can occur with strong oxidizing agents, metal salts, peroxides, and sulfides.
  • Fire HazardFlash point data for Zidovudine are not available; however, Zidovudine is probably combustible.
  • Pharmaceutical ApplicationsAn analog of thymidine formulated for oral or intravenous use.
  • PharmacokineticsOral absorption: 65%
    Cmax 300 mg twice daily: 2.3 mg/L
    Plasma half-life: 1.1 h
    Volume of distribution: 1.6 L/kg
    Plasma protein binding; 34–38%
    Absorption and distribution
    It is absorbed rapidly and almost completely following oral administration. Absorption is not significantly affected by food. It appears to undergo widespread body distribution. CNS penetration is fairly good. The semen:plasma ratio varies from 0.95 to 13.5 (mean 5.9). It is secreted into breast milk.
    Metabolism and excretion
    Following hepatic metabolism (glucuronidation), elimination is primarily renal. After oral administration, urinary recovery of zidovudine and its glucuronide metabolite accounted for 14% and 74% respectively of the dose, with a total urinary recovery of 90%.
    In severe renal impairment, clearance was about half that reported in subjects with normal renal function Accumulation may occur in patients with hepatic impairment due to decreased glucuronidation.
  • Clinical UseTreatment of HIV infection in adults and children (in combination with other antiretroviral drugs)
    Reduction of maternal transmission of HIV to the fetus
  • Side effectsIn common with other drugs in this class, use has been associated with episodes of fatal and non-fatal lactic acidosis and hepatomegaly with steatosis. Careful clinical evaluation is needed in patients with evidence of hepatic abnormality. Myelosuppression may occur within the first 4–6 weeks of therapy. Hematological parameters should be monitored during this period, with prompt dose modification or switch if abnormalities are observed. Treatment with reduced doses may be attempted in some patients once bone marrow recovery has been observed. Myopathy is rarely seen with the use of the current dosing regimens.
    Co-administration with drugs known to cause nephrotoxicity, cytotoxicity or which interfere with red or white blood cell number and function may increase the risk of toxicity. Probenecid and trimethoprim may reduce renal clearance of zidovudine, and other drugs that are metabolized by glucuronidation may interfere with its metabolism.
  • Safety ProfileModerately toxic by intravenousroute. Human systemic effects by ingestion: aplasticanemia, changes in blood cell count, convulsions or effect on seizure threshold, headache, nails, retinal changes.Human mutation data reported.
  • Veterinary Drugs and TreatmentsIn veterinary medicine, zidovudine may be useful for treating feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV). While zidovudine can reduce the viral load in infected cats and improve clinical signs, it may not alter the natural course of the disease to a great extent.
Zidovudine Preparation Products And Raw materials
Zidovudine(30516-87-1)Related Product Information
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Company Name:Meryer (Shanghai) Chemical Technology Co., Ltd.
  • Tel:400-660-8290 21-61259100-
  • Company Name:3B Pharmachem (Wuhan) International Co.,Ltd.
  • Tel:18930552037 821-50328103-801
  • Company Name:Hongene Biotechnology Limited
  • Tel:021-64757213
  • Company Name:Chembest Research Laboratories Limited
  • Tel:021-20908456-